Oct 2026· Journal for ImmunoTherapy of Cancer· Vol 14· 0 citations· 53 references
Medicine
TL;DR
SIRPA functions as a previously unrecognized intrinsic regulator of T cell apoptosis in HCC and may enhance anti-tumor immunity by preventing T cell apoptosis, representing a promising immunotherapeutic strategy.
Abstract
Background Immune checkpoint inhibitors provide limited clinical benefit in advanced hepatocellular carcinoma (HCC), highlighting the need to identify additional mechanisms of tumor immune evasion. Methods We performed genome-scale CRISPR-Cas9 knockout library screening to identify genes associated with T cell apoptosis and identified differentially expressed genes in tumor-infiltrating lymphocytes from HCC patients following high-dose interleukin 2 stimulation. Integrative analysis identified signal regulatory protein alpha (SIRPA) as a candidate regulator of T cell apoptosis. SIRPA was functionally validated in vivo and in vitro using Sirpα-/- mice and primary human T cells. Results In vitro, SIRPA deficiency significantly reduced apoptosis in both human and murine T cells, whereas SIRPA overexpression promoted apoptosis. In vivo, T cell-intrinsic loss of Sirpα markedly suppressed tumor growth, and even haploinsufficiency was sufficient to confer a notable antitumor effect. Following macrophage depletion, Sirpα-/- mice exhibited increased frequencies of functional CD8+ T cells in peripheral blood and tumor tissues, accompanied by elevated granzyme B expression, indicating that Sirpα deficiency confers resistance to apoptosis in T cells. Functionally, SIRPA overexpression impaired the cytotoxic activity of TCR-engineered T cells, whereas adoptive transfer of Sirpα-deficient T cells enhanced tumor control. Mechanistically, SIRPA overexpression activated SHP1, leading to inhibition of the PI3K/AKT/FOXO1 signaling pathway, and upregulation of EGR4. Elevated EGR4 interacted with FOXO1 to regulate the Bim/Bcl-2/Bax axis, thereby promoting T cell apoptosis and facilitating tumor immune evasion. Conclusions SIRPA functions as a previously unrecognized intrinsic regulator of T cell apoptosis in HCC. Targeting SIRPA may enhance anti-tumor immunity by preventing T cell apoptosis, representing a promising immunotherapeutic strategy.
Identifying targets to enhance tumor immunity is an urgent need. Although nucleic acid sensors play critical roles in promoting tumor immune clearance, their exceptionally low mutation rate in cancers suggests potential unexplored roles in tumor progression. Here, we demonstrate that the RNA sensor melanoma differentia...
This study uncovers a novel mechanism that CXCR4-enriched B cells in gastric tumor tissues suppress T cell immunity via adenosine-mediated IL-10 production, which may contribute to tumor immune escape and disease progression of GC.
Yu-Xian Li, Yuan Qiu, Hang Zhong et al.· Cellular and Molecular Gastr...· 0 citations
Clear cell renal cell carcinoma (ccRCC) is an immunogenic cancer in which the use of Immune checkpoint inhibitors (ICIs) has provided clinical benefit. However, long-term therapeutic benefit is limited, as some do not respond initially while others develop resistance after treatment. Although extensive studies have bee...
The RPS19‐C5aR1‐macrophage axis fuels HCC immune escape, and SNPSS‐based RPS19 gene‐editing offers a promising strategy to remodel the TME and boost HCC immunotherapy efficacy.
Lei He, Duo Yu, Fei Xie et al.· Advancement of science· 0 citations
Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhi...
Katrine N. Madsen, S. Kashima, H. Soulati et al.· Journal of Clinical Investig...· 0 citations
These findings establish HCC-IN-247 as an activator of the tumor immune microenvironment and provide a preclinical basis for a combined immunotherapeutic approach to HCC.
De-Yu Zhang, Dong-Xin Peng, X. Wang et al.· ACS Nano· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.